JP2007506681A - 抗ｉｌ−２受容体抗体による呼吸器疾患の治療 - Google Patents

抗ｉｌ−２受容体抗体による呼吸器疾患の治療 Download PDF

Info

Publication number
JP2007506681A
JP2007506681A JP2006527166A JP2006527166A JP2007506681A JP 2007506681 A JP2007506681 A JP 2007506681A JP 2006527166 A JP2006527166 A JP 2006527166A JP 2006527166 A JP2006527166 A JP 2006527166A JP 2007506681 A JP2007506681 A JP 2007506681A
Authority
JP
Japan
Prior art keywords
antibody
daclizumab
asthma
patients
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006527166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506681A5 (https=
Inventor
エス． シェイムズ，リチャード
Original Assignee
ピーディーエル バイオファーマ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーディーエル バイオファーマ，インコーポレイティド filed Critical ピーディーエル バイオファーマ，インコーポレイティド
Publication of JP2007506681A publication Critical patent/JP2007506681A/ja
Publication of JP2007506681A5 publication Critical patent/JP2007506681A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2006527166A 2003-09-23 2004-09-21 抗ｉｌ−２受容体抗体による呼吸器疾患の治療 Pending JP2007506681A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50588303P 2003-09-23 2003-09-23
US55297404P 2004-03-12 2004-03-12
PCT/US2004/031640 WO2005030252A1 (en) 2003-09-23 2004-09-21 Treatment of respiratory diseases with anti-il-2 receptor antibodies

Publications (2)

Publication Number Publication Date
JP2007506681A true JP2007506681A (ja) 2007-03-22
JP2007506681A5 JP2007506681A5 (https=) 2007-11-08

Family

ID=34396276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527166A Pending JP2007506681A (ja) 2003-09-23 2004-09-21 抗ｉｌ−２受容体抗体による呼吸器疾患の治療

Country Status (8)

Country Link
US (1) US20050089517A1 (https=)
EP (1) EP1675615A1 (https=)
JP (1) JP2007506681A (https=)
AU (1) AU2004275860A1 (https=)
BR (1) BRPI0414688A (https=)
CA (1) CA2538737A1 (https=)
RU (1) RU2006113701A (https=)
WO (1) WO2005030252A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN106928346B (zh) 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
US20110236381A1 (en) * 2008-12-10 2011-09-29 Stavros Garantziotis Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
EP2710384B1 (en) * 2011-05-12 2017-11-08 Temple University - Of The Commonwealth System of Higher Education Diagnosis and treatment of copd
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
WO2018053029A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR122020025384B1 (pt) 2016-12-13 2022-07-12 Delinia, Inc Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics, Inc. métodos para quantificar proteínas inibidoras inter-alfa
US12478739B2 (en) * 2018-12-29 2025-11-25 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
KR20220079576A (ko) * 2019-10-04 2022-06-13 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd25 항체-메이탄신 접합체 및 이의 사용 방법
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
GB202106254D0 (en) * 2021-04-30 2021-06-16 Teva Uk Ltd Inhaler system
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4473493A (en) * 1981-04-29 1984-09-25 Immunex Corporation Hybridoma antibody which inhibits interleukin 2 activity
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MX9707862A (es) * 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida para el propionato de fluticasona.
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
PT1100829E (pt) * 1998-07-27 2007-12-06 Univ London Utilização de moléculas de ligação à cd25 no tratamento de artrite reumatóide e doenças cutâneas
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008474A2 (en) * 1990-11-20 1992-05-29 The National Heart & Lung Institute Treatment of lung diseases
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients

Also Published As

Publication number Publication date
AU2004275860A1 (en) 2005-04-07
EP1675615A1 (en) 2006-07-05
CA2538737A1 (en) 2005-04-07
US20050089517A1 (en) 2005-04-28
WO2005030252A1 (en) 2005-04-07
RU2006113701A (ru) 2007-11-10
BRPI0414688A (pt) 2006-11-28

Similar Documents

Publication Publication Date Title
US11325972B2 (en) Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody
EP2152290B1 (en) Methods for administering anti-il-5 antibodies
JP2023139071A (ja) Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
JP2016028086A (ja) 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤
TW202304980A (zh) 經修飾的抗ｔｓｌｐ抗體
TW202302143A (zh) 重症肌無力症之治療或預防用之醫藥組合物
SG11202111255YA (en) Methods for treating or preventing asthma by administering an il-33 antagonist
JP2007506681A (ja) 抗ｉｌ−２受容体抗体による呼吸器疾患の治療
JP2022532928A (ja) 全身性硬化症を治療するための方法
JP2024542777A (ja) 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン
WO2018159845A1 (ja) 低用量抗ｃｃｒ４抗体を用いたｈｔｌｖ－１関連脊髄症の予防または治療剤
JP2023505215A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
MXPA06003129A (en) Treatment of respiratory diseases with anti-il-2 receptor antibodies
WO2025226628A1 (en) Use of il-6 inhibitors for preventing or inhibiting lung transplantation rejection in a subject
CN1856325A (zh) 用抗il－2受体的抗体治疗呼吸道疾病
WO2025217677A1 (en) Methods for treating neutrophilic skin conditions
CN120322247A (zh) 用TNFα抗体治疗结节病的方法以及相关组合物和方法
EP4647084A1 (en) Method for treating asthma by using tslp antibody
HK40127979A (zh) 治疗系统性硬化症的方法
TW202509066A (zh) 用抗ｔｓｌｐ抗體治療皮質類固醇依賴性氣喘
CN120000779A (zh) 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途
CN121889429A (zh) 用于治疗嗜酸性肉芽肿性多血管炎的IL-5R-α抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110222